Confidence+ in our support program

Dealing with hyperphosphatemia can be challenging for your patients with end stage renal disease (ESRD). And you can't be with them all the time. That's why we created the FOSRENOL On Track™ Support Program, a support program that reinforces your efforts and provides patients with materials designed to help them manage their condition.

Experience+ with FOSRENOL

  • Available for more than 9 years1
  • Over 5200 patients studied in completed clinical trials2
  • Approved in 20041

Flexible Dosing+ offers options for you and your patients

FOSRENOL tablets are available in multiple dosage strengths, which allows titration with 1 tablet per meal2

  • Recommended starting daily dose is 1500 mg–one 500-mg tablet with or immediately after meals*
  • Titrate as need with 500-mg, 750-mg, or 1000-mg tablets

*Dosing based on 3 meals per day. Number of meals per day may vary. To Achieve certain doses, additional tables may be required.
Dosing should be titrated every 2 to 3 weeks until an acceptable serum phosphorus level is reached. Monitor serum phosphorous levels as needed during dose titration and on a regular basis thereafter. Doses were generally titrated in increments of 750 mg/day. In clinical studies, most patients required a total daily dose of 1500-3000 mg to reduce serum phosphorus levels to <6.0 mg/dL.

To learn more about dosing with FOSRENOL go to


  • FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Important Safety Information

  • FOSRENOL is contraindicated in patients with bowel obstruction, ileus, and fecal impaction.
  • Serious cases of gastrointestinal obstruction, ileus, and fecal impaction have been associated with lanthanum use, some requiring surgery or hospitalization. Risk factors include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications.
  • Instruct patients to chew or crush the tablet completely to reduce the risk of serious adverse gastrointestinal events. Advise patients with poor dentition that they may crush tablets completely. Advise patients to take FOSRENOL with or immediately after meals.
  • Patients with acute peptic ulcer, ulcerative colitis, Crohn’s disease, or bowel obstruction were not included in FOSRENOL clinical studies.
  • FOSRENOL has radio-opaque properties and may give the appearance typical of an imaging agent during abdominal X-ray procedures.
  • The most common adverse reactions seen with FOSRENOL in clinical trials included nausea, vomiting, diarrhea, and abdominal pain.
  • There is potential for FOSRENOL to interact with:
    • compounds that bind to cationic antacids (ie, aluminum-, magnesium-, or calcium-based)
    • oral quinolone antibiotics
    • thyroid hormone replacement therapy
    These concomitant medications should be dosed separately from FOSRENOL to avoid drug interactions. See the Full Prescribing Information for dosing recommendations.
  • FOSRENOL is Pregnancy Category C. FOSRENOL is not recommended for use during pregnancy. It is not known whether FOSRENOL is excreted in human milk. Use caution when prescribing FOSRENOL to a nursing woman.
  • The safety and efficacy of FOSRENOL in pediatric patients have not been established. The use of FOSRENOL in this population is not recommended.

Please click here for Full Prescribing Information for FOSRENOL (lanthanum carbonate).

Enroll Now

Help your patients get started on the FOSRENOL On Track™ Support Program.

Shire Cares: Patient Assistance & Support Program. Learn More


  1. Center for Drug Evaluation and Research. FOSRENOL approval letter. US Food and Drug Administration website. Accessed June 17, 2014
  2. FOSRENOL [package insert]. Wayne, PA: Shire US Inc.; 2012.

The site you are accessing is maintained by a third party over whom Shire has no control. Shire does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site.

Shire is not responsible for third-party content or the consequences of your use thereof.

Do you wish to continue?